As previously discussed, since PD-L1 is expressed in ~40% of resected human ICC and is associated with poor prognosis, we anticipate that targeting both the PlGF and PD-L1 axes improve ICC treatment outcomes when compared to PlGF blockade alone25. This evidence concerns the gene PGF and intrahepatic cholangiocarcinoma.